BioSpace News Archive

Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator vaccine.

RELIEF THERAPEUTICS Holding SA is pleased to recognize Rare Disease Day 2023 and announce the U.S. availability of the new PKU GOLIKE™ bars, a medical food for the dietary management of phenylketonuria.

Laevoroc Immunology announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for LR 09, a novel metabolic immune checkpoint inhibitor, for the treatment of patients with haematological malignancies who are diagnosed with a relapse after allogeneic stem cell transplant.

HUTCHMED Limited reports its financial results for the year ended December 31, 2022 and provides updates on key clinical and commercial developments.

Cancer is an unfortunate reality that has touched many of us at some point. If you or a loved one has cancer, you may have heard or read that clinical trials can provide access to innovative treatments.

United Therapeutics Corporation announced that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 43rd Annual Health Care Conference in Boston.

Theratechnologies Inc. today announced that it has entered into a first amendment to its credit agreement dated July 20, 2022 (the “Credit Facility”) with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced top-line results from a 12-month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug, in dry eye disease patients.

Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023.